The rapidly growing popularity of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has sparked discussions about lesser-known side effects that are now coming to light as so many patients take these drugs for diabetes and obesity. There is also the potential for more patients to take them as intended as they are being evaluated in hepatology […]